Transfers of Value to Healthcare Professionals
Supporting Healthcare Professionals (Transfers of Value)
Bayer Australia is committed to fostering transparency in all relationships with HealthCare Professionals (HCPs) and strives to ensure trust within the innovative pharmaceutical industry.
Collaborative Research Achieving Positive Patient Outcomes
The ongoing collaboration between the pharmaceutical industry and HCPs has delivered numerous innovative medicines and changed the way many diseases impact patients’ lives. This has been achieved through Bayer’s continued commitment to sponsoring clinical trials and real life evidence, supporting the development and understanding of new treatments for management of disease.
Bayer Australia is dedicated to working closely with HCPs to support their continuous education to assist in keeping them informed of the latest advances in medicines. This is key to achieving better patient outcomes.
Pharmaceutical Industry – Creating consistency through regulation
When collaborating with medical experts, we comply with existing laws and regulations that clearly outline the interaction between industry and healthcare professionals.
In Australia, the pharmaceutical industry is regulated by the Medicines Australia Code of Conduct (www.medicinesaustralia.com.au). Medicines Australia provide the minimum requirements for interactions with HCPs. Adherence to these guidelines Is mandatory.
Medicines Australia – HCP Payments and Transfer of Value Report
Globally Bayer has undertaken to be open and transparent when providing a reportable payment or transfer of value to a healthcare professional. This is also consistent with our local commitment as a member of Medicines Australia. Reportable payments or transfers of value are:
- Payments for the provision of services such as giving a lecture, chairing an educational meeting, providing advice as a member of an Advisory Board or as a Consultant
- Airfares, accommodation and/or conference registration fees to attend medical education as part of those services.
Bayer Australia has prepared the report for publication in accordance with the Medicines Australia Code of Conduct, Edition 18 and Australia’s Privacy legislation. The report identifies healthcare professionals by name where their consent has been provided. Where consent has not been provided the information is reported in aggregate.
From 1 October 2016, reporting these payments will be mandatory – details will be reported because healthcare professionals should reasonably expect that all reportable payments or transfers of value will be disclosed for each healthcare professional, by name.
The report is designed to be read on this website. It is also provided as a downloadable CSV file.
To comply with our privacy obligations, the report may be amended from time to time. The report here contains the most up to date information. Any use or disclosure of the data by a third party is the responsibility of that third party, who must comply with the Australian Privacy Act 1988.
For further information about the details in the report, please go to medicinesaustralia.com.au.
The report for activities and payments made are available here. This report will be available for at least three years from the date of publication.
Please click on the relevant link below to access the HCP Payments and Transfer of Value Report:
HCP Payments and Transfer of Value Report – Nov 2016 – April 2017 – CSV File
HCP Payments and Transfer of Value Report – Nov 2016 – April 2017 – PDF File
HCP Payments and Transfer of Value Report – 1 May 2016 – 31 October 2016 – CSV File
HCP Payments and Transfer of Value Report – 1 May 2016 – 31 October 2016 – PDF File
HCP Payments and Transfer of Value Report – 1 October 2015 – 30 April 2016 – CSV File
HCP Payments and Transfer of Value Report – 1 October 2015 – 30 April 2016 – PDF File